Navigation Links
Topline Results from Phase 2 Clinical Trial of Oral NKTR-118 Presented at 20th American Academy of Pain Management Annual Clinical Meeting (AAPM) in Phoenix
Date:10/10/2009

) 2009 Annual Scientific Meeting to be held in San Diego, California on October 27, 2009. The data will be presented by Dr. Lynn Webster, medical director of Lifetree Clinical Research and lead clinical investigator of the Phase 2 trial.

On September 21, 2009, Nektar Therapeutics announced it had entered into an exclusive worldwide license agreement with AstraZeneca for its NKTR-118 and NKTR-119 programs.

About Opioid-Induced Constipation

The oral peripheral antagonist NKTR-118 targets mu-opioid receptors within the enteric nervous system, which mediate opioid-induced bowel dysfunction, a symptom complex resulting from opioid use that encompasses symptoms such as constipation, bloating, abdominal cramping, and gastroesophageal reflux. Constipation is the hallmark of this syndrome and is generally its most prominent component. In patients who take opiates chronically for pain management, anywhere from 45-90% of patients will develop debilitating constipation associated with other symptoms of opioid-induced bowel dysfunction as a result of the drug binding to the mu-opioid receptor in the gut(1).

According to IMS Health, about 230 million prescriptions were written for opioids in 2007 in the United States alone. Currently, there are no oral drugs approved that are indicated to treat opioid-induced constipation (OIC). Opioid bowel dysfunction and OIC can significantly impact quality of life and increase healthcare utilization.

NKTR-119 is an investigational drug candidate that is a co-formulation of oral NKTR-118 and an opioid analgesic. The product is designed to provide good analgesic properties in the chronic treatment of moderate to severe pain patients while avoiding the debilitating side effects that are common with opioid use, such as constipation and other symptoms of bowel dysfunction.

About Nektar

Nektar Therapeutics is a biopharmaceutical company dev
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Topline Findings from Comparative Analysis of INVEGA(TM) and Quetiapine in Schizophrenia to be Postered at the 20th Annual U.S. Psychiatric and Mental Health Congress
2. HerbalScience Releases Results of Pilot Clinical Study on Efficacy of Its Proprietary Elderberry Extract in Addressing Flu-Like Symptoms
3. ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
4. Transdel Pharmaceuticals to Host Conference Call and Webcast on Tuesday, October 6, 2009 to Announce Top-Line Phase 3 Study Results for Lead Topical Pain Drug Ketotransdel(R)
5. Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial
6. Biotel Announces Fourth Quarter and Year End Results
7. Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference
8. BioMarin to Host Third Quarter 2009 Financial Results Conference Call and Webcast on Wednesday, October 28 at 5:00 p.m. ET
9. InteKrin Therapeutics Presents Positive INT131 Phase 2b Results at the 45th Annual European Association for the Study of Diabetes Meeting
10. Encouraging HIV/AIDS Vaccine Trial Results Support GeoVax Labs, Inc. Strategy
11. Sinobiopharma Reports Highlights From Audited Financial Results for the Fiscal Year Ended May 31, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... December 16 Eppendorf has initiated ... Verigene(R) SP systems for,infringement of European patent ... for the,identification and/or the quantification of a ... all imports of the respective products into ... are required to confiscate any,violating products. , ...
(Date:12/15/2009)... SAN MARINO, Calif., Dec. 15 Epeius ... of targeted genetic medicine, gained international validation of ... Rexin-G , when scientists around the world ... be a major locus of cancer pathogenesis and ... anti-cancer therapies. Recently, scientists at the NIH National ...
(Date:12/15/2009)... -- China Sky One,Medical, Inc. ("China Sky One ... a,leading fully integrated pharmaceutical company developing and producing,over-the-counter ... today,announced that the Company has 30 medicines that ... National Basic Medical Insurance, Industrial Injury Insurance,and Maternity ... The 30 medicines treat a variety of common ...
(Date:12/15/2009)... CHARLOTTESVILLE, Va., Dec. 15 AstraZeneca ... University of Virginia (UVa) in Charlottesville, today ... strategic research collaboration to enhance development of ... (CAD) with a secondary focus on peripheral ... ) ,, The collaborative preclinical research ...
Breaking Biology Technology:Eppendorf Successfully Initiates Import ban Against Nanosphere, Inc. for the Countries of the European Union 2Scientists Rediscover Gene Target for Cancer Therapy 2Scientists Rediscover Gene Target for Cancer Therapy 3China Sky Medical, Inc. Has 30 Medicines that will Be Included in China's National Insurance Directory 2China Sky Medical, Inc. Has 30 Medicines that will Be Included in China's National Insurance Directory 3AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease 2AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease 3
... Waters Corporation,(NYSE: WAT ) today ... of melamine in,infant formula and liquid milk ... Science and Technology (M.O.S.T.). The new method ... tandem,quadrupole mass spectrometry (UPLC/MS/MS) operated in Multiple ...
... Support Phase II Trial of Novel Antidepressant,Tyrima(TM) and ... PARK, N.C., Oct. 17 CeNeRx BioPharma,Inc., a ... diseases of the central nervous system (CNS), today,announced ... Existing,investors Aisling Capital, L Capital Partners and Pappas ...
... A team of researchers from Penn State and the University ... use light to control certain proteins that catalyze biochemical reactions. ... successfully controlling the activity of a protein using light," said ... of the Eberly Family Chair in Chemistry, and one of ...
Other Biology Technology:Waters Publishes Rapid and Specific Method of Detection for Melamine in Infant Formula and Liquid Milk, in Support of China's Ministry of Science and Technology 2CeNeRx BioPharma Completes $15 Million Series B Financing 2CeNeRx BioPharma Completes $15 Million Series B Financing 3CeNeRx BioPharma Completes $15 Million Series B Financing 4Scientists use light to control proteins 2
(Date:12/16/2009)... N.J., Dec. 3 BIO-key International, ... in wireless public safety and finger-based biometric ... its shareholders at a Special Shareholder Meeting ... company,s Law Enforcement Division to Interact911 Mobile ... were cast in favor and 1.2% were ...
(Date:12/16/2009)... -- European Union (EU) member states are ... are increasingly subjected to unauthorised immigration and ... technology security and IT-based systems will boost ... http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) ,, New analysis from Frost ... Security Market Assessment - European Union , ...
(Date:12/15/2009)... Economics, environmental impacts, social dynamics, and production levels ... success of an agroecosystem. Positive or negative, these ... and social groups to continuously adapt farming and ... Experiential learning theory suggests that knowledge is gained ... lessons are especially valuable for environmental and agricultural ...
Breaking Biology News(10 mins):BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 3Increased Spending on the EU's External Borders to Drive the Border Security Market, Says Frost & Sullivan 2Increased Spending on the EU's External Borders to Drive the Border Security Market, Says Frost & Sullivan 3Experiential learning teaches change and adaptation 2Toward bold new anti cancer medicines 10561 1Attention deficit hyperactivity problems associated with low folate levels in pregnant women 10559 1UD start up company prepares to commercialize novel detector for medical military applications 10557 1UD start up company prepares to commercialize novel detector for medical military applications 10557 2UD start up company prepares to commercialize novel detector for medical military applications 10557 3UD start up company prepares to commercialize novel detector for medical military applications 10557 4
... Circular markings on creatures such as butterflies are ... not because they mimic the eyes of the ... in the journal, Behavioral Ecology[1]. Zoologists based at ... about why these markings are effective against predators. ...
... given weekday, about a quarter of the U.S. population is ... million students in K-12 public schools, six million more in ... teachers. Education is a big business, but a struggling one. ... system, can neuroscience provide insights and solutions" , On ...
... free milk and had higher intakes of calcium and vitamin ... lower risk for developing hypertension or high blood pressure, according ... journal, Hypertension. , After examining the diets of nearly ... who consumed more low-fat milk and milk products and had ...
Other Biology News:Zoologists challenge longstanding theory that 'eyespots' mimic the eyes of predators' enemies 2'Brains R Us': Neuroscience and education town hall 2Drinking milk may help ease the pressure 2
EnzChek Ultra Xylanase Assay Kit *500 assays*...
Goat polyclonal to p27 KIP 1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: C-KRPATDDS STQNK, corresponding to Internal sequence amino acids 153-165 of Human p27 KIP 1 ...
Defender against cell death 1...
Wnt-1 (G-19)...
Biology Products: